NSE: SOLARA | BSE: 541540

Mid-range Performer

Download real time

560.05 1.75 (0.31%)

26.48% Gain from 52W Low

54,723 NSE+BSE Volume

NSE 26 Dec, 2025 3:31 PM (IST)

2,491.6

Market Cap

Above industry Median

Beta 1Year

High Volatility

Solara Active Pharma Sciences Ltd. share price target and research reports

Name: Latest research reports of Solara Active Pharma Sciences Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Solara Active Pharma Sciences Ltd.
Rating: 5
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for SOLARA, BSE:541540 Solara Active Pharma Sciences Ltd.

Search Inside the pdf :

Solara Active Pharma Sciences Ltd.

27 Jan 2023, 12:00AM

560.05

0.31%

On the path to gradual recovery

Buy: Solara Active Pharma Scien...

Target

ICICI Securities Limited

Solara Active Pharma’s (Solara) Q3FY23 performance was above our estimates across all parameters. Revenue was up 16.7% QoQ to Rs.3.9bn (I-Sec: Rs.3.8bn)) with strong recovery in regulated markets.

Solara Active Pharma Sciences Ltd. is trading below all available SMAs

Solara Active Pharma Sciences Ltd.

10 Nov 2022

560.05

0.31%

Gradual recovery; valuations comfortable

Buy: Solara Active Pharma Scien...

Target

ICICI Securities Limited

Solara Active Pharma’s (Solara) Q2FY23 performance was below our estimates across all parameters.

Promoters unpledged 3.63% of shares in last quarter. Total pledge stands at 35.32% of promoter holdings

Solara Active Pharma Sciences Ltd.

05 Aug 2022

560.05

0.31%

Slow recovery in base; Valuations comfortable

Buy: Solara Active Pharma Scien...

ICICI Securities Limited

Solara Active Pharma’s (Solara) Q1FY23 performance was below our estimates across all parameters. Revenue declined 18.6% YoY (-8.5%QoQ) to Rs.3.3bn (I-Sec: Rs.3.8bn) with slower recovery across segments.

Solara Active Pharma Sciences Ltd. is trading below all available SMAs

Solara Active Pharma Sciences Ltd.

02 May 2022

560.05

0.31%

Result Update:Solara Active

Not Rated: Solara Active Pharma Scien...

Axis Direct

The company's business seems to have lost momentum due to lower demand for Ibuprofen as well a lack of pricing power in the non-regulated market, and higher input and logistic costs. The company's margins are also at risk, forcing us to keep this scrip Under Review for now.

Promoters unpledged 3.63% of shares in last quarter. Total pledge stands at 35.32% of promoter holdings

Solara Active Pharma Sciences Ltd.

12 Nov 2021

560.05

0.31%

Result Update:Solara Active

Hold: Solara Active Pharma Scien...

Target

Axis Direct

We expect the whole API industry to continue facing challenges due to a fall in realization as well as an increase in cost pressure. We foresee the situation to continue for the next 2-3 quarters and therefore recommend a HOLD rating on the stock with the target price of Rs 1,300/share.

Promoters unpledged 3.63% of shares in last quarter. Total pledge stands at 35.32% of promoter holdings

Solara Active Pharma Sciences Ltd.

05 Aug 2021

560.05

0.31%

Result Update:Solara Active

Hold: Solara Active Pharma Scien...

Axis Direct

We expect Gross Margins to be impacted due to an increase in revenue share from non-regulated markets and an increase in raw material prices going onwards. Hence, we recommend a HOLD rating on the stock with a target price of INR 1,670 (PE 20x for FY23EPS).

Promoters unpledged 3.63% of shares in last quarter. Total pledge stands at 35.32% of promoter holdings

Solara Active Pharma Sciences Ltd.

04 Aug 2021

560.05

0.31%

Comprehensive approach in API/CRAMS to drive growth

Buy: Solara Active Pharma Scien...

Motilal Oswal

Comprehensive approach in API/CRAMS to drive growth Motilal Oswal values your support in the Asiamoney Brokers Poll 2021 for India Research, Sales, Corporate Access and...

Solara Active Pharma Sciences Ltd. is trading below all available SMAs

Solara Active Pharma Sciences Ltd.

07 May 2021

560.05

0.31%

Result Update:Solara Active

Hold: Solara Active Pharma Scien...

Recommendation

Axis Direct

We expect gross margins to be impacted due to an increase in revenue share from the non-regulated market going onwards, therefore recommend HOLD' with a target price of Rs 1,670/share (PE 20x for FY23EPS).

Promoters unpledged 3.63% of shares in last quarter. Total pledge stands at 35.32% of promoter holdings

Solara Active Pharma Sciences Ltd.

24 Feb 2021

560.05

0.31%

Company Update:Solara Active

Buy: Solara Active Pharma Scien...

Axis Direct

Solara has built a strong and enduring platform that consists of two essential pieces, the outside in and the inside out. In outside in, Solara global presence long-standing customer relationships, breadth of product portfolio.